MedTrace Logo

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-03-02

No results posted yet for this study

Summary

This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Conditions

Interventions

DRUG

Brigatinib

Treatment with Brigatinib

DRUG

Tyrosine kinase inhibitor

Treatment with any TKI

Sponsors & Collaborators

  • Thoraxklinik-Heidelberg gGmbH

    collaborator OTHER

  • Takeda

    collaborator INDUSTRY

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. · Institut für Klinische Krebsforschung IKF GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318938 on ClinicalTrials.gov